Scientists have engineered a tobacco relative to produce five psychedelic tryptamines, compounds normally scattered across fungi, plants, and animals, in a single crop. The work, published in Science Advances, used a technique called agroinfiltration to temporarily switch on nine foreign genes inside the plant Nicotiana benthamiana, achieving complete biosynthesis of all five substances without permanent genetic modification. The result is the first demonstration that a single plant chassis can reconstruct psychedelic pathways from three biological kingdoms at once, a technical feat that could reshape how these increasingly studied compounds are manufactured.
Three Kingdoms, One Plant
The core achievement is deceptively simple in concept but technically demanding: researchers introduced nine heterologous genes into Nicotiana benthamiana, enabling the plant to synthesize five psychedelic tryptamines. Those compounds trace their natural origins to fungi, plants, and animals, meaning the engineered tobacco relative effectively consolidated biosynthetic machinery from three separate kingdoms into its own leaf tissue.
Agroinfiltration, the delivery method, works by using bacteria to ferry foreign genes into the plant’s cells. Because the expression is transient rather than stable, the introduced genes are active for a limited window, long enough to produce the target molecules but without permanently altering the plant’s genome. This approach sidesteps some of the regulatory and biological complications of stable transformation, though it also means each production run requires a fresh round of gene delivery.
The compounds sourced from these three kingdoms include psilocybin, which occurs naturally in certain mushroom species, and DMT and 5-MeO-DMT, which are found in various plants and, in the case of 5-MeO-DMT, in toad secretions. By stacking the enzymatic steps for all five molecules in a single host, the team demonstrated that transient plant expression systems can handle far more pathway complexity than earlier experiments had attempted.
Why Tobacco Is the Biologist’s Workhorse
Nicotiana benthamiana has long been called the “fruit fly of the plant kingdom” because of the ease with which it can be genetically engineered. That reputation rests on practical advantages: the plant grows quickly, tolerates the introduction of multiple foreign genes at once, and produces enough leaf biomass for analytical chemistry workflows to detect and quantify the resulting molecules.
A recent review in aBIOTECH explains why this species has become a preferred chassis for rapid pathway reconstruction. Speed is the primary draw. Where stable genetic lines in crops can take months or years to develop, transient expression in N. benthamiana delivers results within days, making it ideal for testing whether a proposed biosynthetic route actually works before committing to longer-term engineering. Gene stacking, the ability to introduce several pathways simultaneously, is another advantage that directly enabled the five-compound result reported here.
The same lab group, led by Asaph Aharoni at the Weizmann Institute of Science, previously demonstrated pathway reconstruction for the hallucinogen mescaline in both N. benthamiana and yeast. That earlier work, with lead author Paula Berman, established the team’s capacity to move between plant and microbial hosts depending on the target molecule, and it set the stage for the more ambitious multi-compound effort now published.
Plants Versus Yeast for Drug Production
Most prior efforts to engineer psychedelic production have relied on microbial hosts, particularly yeast. Engineered strains of Saccharomyces cerevisiae have successfully produced tryptamine-scaffold molecules including psilocybin, and yeast offers clear advantages in fermentation-based scale-up: bioreactors are well understood, yields can be optimized through established metabolic engineering tools, and production cycles are fast. A review in FEMS Yeast Research compares plant-based and yeast-based production in terms of yield, scalability, and pathway complexity.
The plant-based approach has a different set of strengths. N. benthamiana can accommodate larger, more complex pathways without the extensive codon optimization and promoter tuning that yeast often requires. It also provides a eukaryotic cellular environment with protein-folding and post-translational modification machinery closer to the organisms where these compounds evolved. For initial pathway prototyping, the plant system is faster to set up, even if per-gram yields currently lag behind optimized yeast strains.
The tension between these two platforms matters because the therapeutic pipeline for psychedelics is expanding rapidly, and the production method will shape cost, purity, and regulatory approval timelines. Researchers at the University of Queensland have noted that N. benthamiana can potentially produce large quantities of drugs cheaper and more sustainably than some industrial manufacturing methods. Whether that potential translates into practice depends on whether yields from transient expression can be pushed high enough, or whether stable transformation lines will be needed to close the gap with fermentation.
Why the Compounds Matter Clinically
The five tryptamines assembled in the tobacco relative sit at the center of a resurgent interest in psychedelic-assisted therapy. Psilocybin and DMT analogs are being investigated for treatment-resistant depression, post-traumatic stress disorder, and substance use disorders, while 5-MeO-DMT has drawn attention for its rapid onset and short duration of action. Each compound interacts with serotonin receptors in slightly different ways, and medicinal chemists are exploring how structural tweaks might preserve therapeutic benefits while reducing intense hallucinogenic effects.
A recent perspective in Nature Synthesis outlines how synthetic chemistry and bioengineering are converging around these molecules. Traditional total synthesis can deliver highly pure compounds but often involves multi-step routes, expensive catalysts, and significant chemical waste. Biocatalytic production in cells, whether yeast or plants, promises cleaner processes and easier access to analog libraries, especially when enzymes can be swapped or mutated to generate new variants directly in the host organism.
Reliable access to clinical-grade material is a practical bottleneck. Many psychedelic compounds are controlled substances, and sourcing them from wild organisms raises ecological and ethical concerns, particularly in the case of toad-derived 5-MeO-DMT. A plant chassis that can produce multiple tryptamines from simple sugar inputs offers a way to decouple research supply from vulnerable ecosystems and to standardize quality across batches.
From Proof of Concept to Production Platform
For now, the N. benthamiana system is best viewed as a discovery and prototyping tool rather than an industrial workhorse. Transient expression requires repeated agroinfiltration, and the yields reported in the Science Advances study are modest compared with mature microbial fermentation processes. Scaling up would mean growing large volumes of plants, managing infection logistics at greenhouse or field scale, and developing efficient downstream extraction methods that meet pharmaceutical standards.
Still, the ability to reconstruct multi-step pathways spanning three biological kingdoms in a single plant is a clear signal of what is technically possible. The same framework could be extended beyond psychedelics to other specialized metabolites, such as alkaloids, terpenoids, and complex glycosides that remain difficult to make in microbes. By rapidly testing different enzyme combinations in N. benthamiana leaves, researchers can identify high-performing pathway designs before porting them into yeast or bacteria for large-scale manufacture.
In parallel, plant biotechnologists are exploring stable transformation strategies that would embed these complex pathways directly into the N. benthamiana genome. Such lines could, in principle, be cultivated like conventional crops, turning fields or vertical farms into living factories for high-value molecules. The trade-off is time: generating, characterizing, and regulating stable engineered plants is slower and more capital-intensive than transient experiments, so the transient system is likely to remain central for early-stage work.
Regulatory and Ethical Dimensions
Engineering plants to produce controlled psychoactive substances raises regulatory questions that go beyond standard agricultural biotechnology. Containment, diversion risk, and cross-pollination with related species will all be scrutinized if psychedelic-producing crops move outside secure growth facilities. However, the transient nature of agroinfiltration offers one built-in safeguard: without ongoing bacterial delivery, the plants revert to their non-psychedelic state in a matter of days.
Ethically, plant-based production could reduce pressure on organisms currently harvested for psychedelic compounds, such as certain cacti and amphibians, and provide more equitable access to medicines if therapies prove effective. At the same time, expanding supply chains for potent psychoactives will require careful coordination among scientists, regulators, and communities to ensure that commercialization does not outpace evidence or safety frameworks.
A New Chapter for Plant Biofactories
The Nicotiana benthamiana experiment underscores how far plant synthetic biology has come in a short time. What began as a convenient testbed for single-gene expression has evolved into a platform capable of assembling intricate metabolic circuits that rival, and in some respects surpass, microbial systems. By knitting together enzymes from fungi, plants, and animals inside a single leaf, researchers have shown that the boundaries between biological kingdoms are increasingly technical rather than conceptual.
Whether future psychedelic medicines are ultimately brewed in stainless-steel tanks of yeast or grown in rows of engineered tobacco relatives, this work expands the menu of options. It demonstrates that plants can shoulder a surprising share of the metabolic heavy lifting and that complex natural products need not remain tied to the rare organisms that first evolved them. As interest in psychedelic therapeutics accelerates, the humble lab tobacco plant is quietly positioning itself as one of the field’s most versatile allies.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
